JV GL1
Alternative Names: JV-GL1Latest Information Update: 22 May 2024
At a glance
- Originator JeniVision
- Class Antiglaucomas; Eye disorder therapies
- Mechanism of Action Prostaglandin E EP2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 10 May 2024 JeniVision terminates a phase-I/II trial in Open-angle glaucoma in USA (Ophthalmic) due to awaiting transition to part 2 (NCT04761705)
- 10 Mar 2021 Phase-I/II clinical trials in Ocular hypertension in USA (Ophthalmic) (NCT04761705)
- 24 Feb 2021 Preclinical trials in Ocular hypertension in USA (Ophthalmic) prior to February 2021